Drug Price Trends for ACETAZOLAMIDE ER

Average Pharmacy Cost for ACETAZOLAMIDE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ACETAZOLAMIDE ER 500 MG CAP	29033-0030-01	0.31581	EACH	2025-04-23
ACETAZOLAMIDE ER 500 MG CAP	42571-0243-01	0.31581	EACH	2025-04-23
ACETAZOLAMIDE ER 500 MG CAP	23155-0787-01	0.31581	EACH	2025-04-23
ACETAZOLAMIDE ER 500 MG CAP	50268-0042-11	0.31581	EACH	2025-04-23
ACETAZOLAMIDE ER 500 MG CAP	16729-0331-01	0.31581	EACH	2025-04-23
ACETAZOLAMIDE ER 500 MG CAP	70710-1591-01	0.31581	EACH	2025-04-23

Acetazolamide Market Analysis and Price Projections

Introduction to Acetazolamide

Acetazolamide, a carbonic anhydrase inhibitor, is a versatile medication used in the treatment of various medical conditions, including glaucoma, altitude sickness, certain types of seizures, and edema. Here, we delve into the market analysis and price projections for this essential drug.

Market Size and Growth Projections

The global acetazolamide market has been experiencing steady growth, driven by several key factors. As of 2022, the market size was valued at USD 263.04 billion and is projected to reach USD 499.69 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.60% from 2023 to 2030[1].

Another perspective indicates that the market size was valued at a significantly lower figure, USD 175.7 million in 2022, and is expected to reach USD 235.47 million by 2032, with a CAGR of 2.7% during the forecast period[5]. The discrepancy in market size values highlights the complexity and variability in market assessments, but both indicate a positive growth trajectory.

Key Drivers of Market Growth

Several factors are driving the growth of the acetazolamide market:

• Increasing Prevalence of Glaucoma: The rising incidence of glaucoma, particularly among the aging population, is a significant driver. By 2040, an estimated 111.8 million people are expected to be affected by glaucoma worldwide[4].
• Altitude Sickness and Adventure Tourism: The expansion of adventure and travel industries at high altitudes increases the demand for acetazolamide as a preventive measure and treatment for altitude sickness[1].
• Neurological Disorders: Acetazolamide's use in treating certain types of seizures and as an adjunct therapy in neurological disorders also contributes to its market growth[1].
• Emerging Markets and Healthcare Access: Growing healthcare infrastructure and increasing access to healthcare in emerging markets offer untapped opportunities for acetazolamide manufacturers[1].

Regional Analysis

The global acetazolamide market is segmented into several regions, each with its own dynamics:

• North America: This region, including the United States and Canada, is a significant market due to advanced healthcare infrastructure, high awareness of medical conditions, and a large aging population[1].
• Europe: Europe is another prominent market, characterized by strict regulatory standards and a high prevalence of glaucoma and other related conditions[1].
• Asia Pacific: This region is expected to be a conducive market for acetazolamide due to growing healthcare infrastructure, high prevalence of glaucoma, and associated risk factors such as diabetes and high blood pressure[4].

Price Projections and Affordability

The prices of acetazolamide vary based on the formulation and quantity:

• Oral Tablets: For example, a 125 mg oral tablet can cost around $13 for a supply of 6 tablets, while a 250 mg tablet can cost approximately $45 for 100 tablets[2].
• Intravenous Powder: The cost for an intravenous powder for injection can range from $32.96 to $54.34 per unit[2].
• Extended Release Capsules: The price for extended release capsules can range from $36.98 for 20 capsules to $91.94 for 60 capsules[2].

Discount programs and patient assistance plans can significantly reduce the cost of acetazolamide, making it more affordable for patients. However, no specific patient assistance programs were found for this medication[2].

Competitive Landscape

The acetazolamide market is competitive, with several key players:

• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sandoz International GmbH (A division of Novartis)
• Apotex Inc.
• Zydus Cadila
• Endo Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Strides Pharma Science Limited
• Hikma Pharmaceuticals PLC
• Avet Pharmaceuticals Inc.[1]

These companies engage in various strategies such as product benchmarking, SWOT analysis, and market share analysis to maintain their competitive edge.

Extended Applications and Research

Recent research has highlighted the potential of acetazolamide in new treatment modalities. For instance, studies have shown that acetazolamide can help overcome resistance to the chemotherapy drug temozolomide (TMZ) in the treatment of gliomas, offering a 30 to 40 percent increase in survival rates in animal models[3][4].

Regulatory Landscape

The pharmaceutical industry, including the acetazolamide market, is heavily regulated. Compliance with regulatory requirements is crucial for manufacturers, and obtaining approvals for new formulations or indications can be a lengthy and complex process. This regulatory environment poses challenges but also ensures high standards of safety and efficacy[1].

Market Attractiveness

The market attractiveness of acetazolamide is influenced by several factors, including the prevalence of medical conditions it treats, evolving healthcare infrastructure, advancements in medical research, and the regulatory landscape. While the market faces challenges, it also presents opportunities for growth through strategic collaborations with research institutions and healthcare providers[1].

Key Takeaways

• The global acetazolamide market is projected to grow significantly, driven by increasing prevalence of glaucoma, altitude sickness, and neurological disorders.
• Regional markets such as North America, Europe, and Asia Pacific are key contributors to the market growth.
• The competitive landscape is dominated by several major pharmaceutical companies.
• Extended applications in new treatment modalities offer lucrative growth opportunities.
• Regulatory compliance and access to healthcare are critical factors influencing market dynamics.

Frequently Asked Questions (FAQs)

1. What is the projected market size of acetazolamide by 2030? The global acetazolamide market is projected to reach USD 499.69 billion by 2030[1].

2. What is the primary use of acetazolamide? Acetazolamide is primarily used for the treatment of glaucoma, altitude sickness, certain types of seizures, and edema[1][4].

3. Which regions are expected to drive the growth of the acetazolamide market? North America, Europe, and Asia Pacific are expected to be significant drivers of the acetazolamide market growth[1][4].

4. How does acetazolamide help in the treatment of gliomas? Acetazolamide has been shown to help overcome resistance to the chemotherapy drug temozolomide (TMZ) in the treatment of gliomas, resulting in improved survival rates in animal models[3][4].

5. Are there any patient assistance programs available for acetazolamide? No specific patient assistance programs were found for acetazolamide, although discount programs and copay cards can help reduce the cost[2].

Sources:

1. Verified Market Research - Acetazolamide Market Size, Share, Trends, Analysis & Forecast[1]
2. Drugs.com - Acetazolamide Prices, Coupons, Copay Cards & Patient Assistance[2]
3. Coherent Market Insights - Acetazolamide Market Size and Trends[3]
4. Coherent Market Insights - Acetazolamide Market Size, Trends And Forecast To 2026[4]
5. Business Research Insights - Acetazolamide Market Size, Share, Trends, Analysis, 2032[5]